Prostatype Genomics

Prostatype Genomics Equity

The The Equity of Prostatype Genomics (PROGEN.ST) as of Oct 13, 2026 is 26.53 M SEK. In the previous year, The Equity was 33.47 M SEK — a change of -20.74% (lower).

Equity

26.53 MSEK

YoY

-20.74%

Last updated:

In 2025, Prostatype Genomics's equity was 26.53 M SEK, a -20.74% increase from the 33.47 M SEK equity in the previous year.

The Prostatype Genomics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
6.22 M SEK
Jan 1, 2018
8.55 M SEK
Jan 1, 2020
28.29 M SEK
Jan 1, 2021
35.91 M SEK
Jan 1, 2022
26.15 M SEK
Jan 1, 2023
24.67 M SEK
Jan 1, 2024
33.47 M SEK
Jan 1, 2025
26.53 M SEK
The Prostatype Genomics Equity history
YEAREquityYoY
26.53 MSEK-20.74%
33.47 MSEK+35.64%
24.67 MSEK-5.65%
26.15 MSEK-27.17%
35.91 MSEK+26.92%
28.29 MSEK+231.02%
8.55 MSEK+37.34%
6.22 MSEK-58.31%
14.93 MSEK-1,230.76%
-1.32 MSEK—
Access this data via the Eulerpool API
Get Free API Key

Prostatype Genomics Stock analysis

What does Prostatype Genomics do? Prostatype Genomics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Prostatype Genomics's Equity

Prostatype Genomics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Prostatype Genomics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Prostatype Genomics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Prostatype Genomics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Prostatype Genomics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Prostatype Genomics stock

The Equity of Prostatype Genomics is 26.53 M SEK in 2025.

The Equity of Prostatype Genomics changed from 33.47 M SEK to 26.53 M SEK, representing a -20.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.

The Equity's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Prostatype Genomics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Prostatype Genomics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Prostatype Genomics